Rockwell Medical Names Heather Hunter SVP, Chief Corporate Affairs Officer

WIXOM, Mich.--(BUSINESS WIRE)--$RMTI #blooddisorders--Rockwell Medical, Inc. (Nasdaq: RMTI), a commercial healthcare company focused on providing life-sustaining products for patients suffering from blood disorders and diseases associated with the kidney, today announced that Heather Hunter has joined the Company as SVP, Chief Corporate Affairs Officer. In this role, Heather will be responsible for the Company’s investor relations, media relations, government affairs, patient advocacy, communications, and branding.

“Heather brings more than two decades of executive leadership, investor relations and communications expertise to Rockwell, with a wealth of experience in the capital markets and a strong network across the financial community,” said Mark Strobeck, Ph.D., President and CEO at Rockwell. “Heather has a demonstrated track record of success elevating corporate brands, developing and implementing corporate strategy, and driving shareholder value. I look forward to working with Heather as we unlock the value of our product portfolio and development expertise and transition our business towards profitability.”

“I am excited for the path that lies ahead at Rockwell and impressed by all that the Company has achieved in its 25+ year history,” said Heather. “Rockwell is at a critical inflection point as the Company works towards profitability and expands its portfolio of offerings for patients suffering from blood disorders and diseases associated with the kidney. I look forward to working with Mark and the rest of the Rockwell team to catalyze and support the Company’s success now and into the future.”

Prior to joining Rockwell, Heather led communications at Venatorx Pharmaceuticals, a private, pre-commercial anti-infectives pharmaceutical company; Safeguard Scientifics (NYSE:SFE), a growth equity investor focused on early- and growth-stage healthcare and technology companies; and W.P. Carey (NYSE:WPC), one of the largest net lease real estate investment trusts. Heather is currently an Advisory Board Member at Journal My Health, a digital health platform designed to empower patients with chronic health conditions to use their data to achieve better health outcomes, and a Managing Director at Golden Seeds, an angel investment firm that funds revenue-stage, women-led and women-founded companies. Heather was named to the Philadelphia Business Journal ‘40 Under 40’ list in 2017 and received a B.A. in History from Yale University.

About Rockwell Medical

Rockwell Medical is a commercial healthcare company focused on providing life-sustaining products for patients suffering from blood disorders and diseases associated with the kidney. Rockwell is the second largest supplier of acid and bicarbonate concentrates for dialysis patients in the United States. The Company is developing and commercializing a next-generation, proprietary parenteral iron technology platform, Ferric Pyrophosphate Citrate (“FPC”), which has the potential to transform treatment options for iron deficiency in multiple disease states, reduce healthcare costs and improve patients' lives. Rockwell has two FDA-approved therapies indicated for patients undergoing hemodialysis, which are the first two products developed from the FPC platform. Rockwell is also advancing its FPC platform by developing FPC for the treatment of iron deficiency anemia in patients outside of dialysis, who are receiving medications in the home infusion setting. For more information, visit www.RockwellMed.com.

Forward-Looking Statements

Certain statements in this press release may constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as, "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "could," "can," "would," "develop," "plan," "potential," "predict," "forecast," "project," "intend," "look forward to," "remain confident" or the negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward looking statements. There can be no assurance that Rockwell Medical will be able to maintain timing for planned clinical trials and regulatory filings, achieve planned cost savings to operate its concentrates business profitability, or achieve the other components of its strategy. While Rockwell Medical believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in Rockwell Medical's SEC filings), many of which are beyond our control and subject to change. Actual results could be materially different. Risks and uncertainties include, but are not limited to those risks more fully discussed in the "Risk Factors" section of our Annual Report on Form 10-K for the year ended December 31, 2021, as such description may be amended or updated in any future reports we file with the SEC. Rockwell Medical expressly disclaims any obligation to update our forward-looking statements, except as may be required by law.

Heather R. Hunter
(248) 432-1362
IR@RockwellMed.com